Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) insider Merdad Parsey sold 164,211 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares of the company's stock, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Merdad Parsey also recently made the following trade(s):
- On Wednesday, November 6th, Merdad Parsey sold 25,590 shares of Gilead Sciences stock. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00.
- On Tuesday, October 1st, Merdad Parsey sold 2,000 shares of Gilead Sciences stock. The stock was sold at an average price of $83.83, for a total value of $167,660.00.
Gilead Sciences Stock Up 0.2 %
Shares of NASDAQ:GILD opened at $92.58 on Friday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The company has a market capitalization of $115.38 billion, a PE ratio of 1,028.67, a P/E/G ratio of 2.87 and a beta of 0.17. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The company's fifty day moving average is $88.26 and its 200-day moving average is $77.69.
The latest trend in real estate
From Pacaso | Ad
These vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, they’re being transformed into fully utilized assets. And there’s one company that’s leading the charge – already welcoming over 1,500 happy homeowners into their co-ownership family, earning $100M in gross profits along the way.
Now, for the first time, this innovative company is opening its doors to public investors. Want to learn more about co-ownership and its potential? Check them out – but be aware: their share price is set to change December 5, so you don’t have long to maximize your stake.
Don’t miss your chance to maximize your stake in this co-ownership revolution.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences's revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the prior year, the company earned $2.29 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 4.37 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date is Friday, December 13th. Gilead Sciences's dividend payout ratio is presently 3,422.22%.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. Avior Wealth Management LLC raised its position in shares of Gilead Sciences by 1.2% during the third quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company's stock worth $782,000 after acquiring an additional 108 shares during the last quarter. Concord Asset Management LLC VA boosted its stake in shares of Gilead Sciences by 3.8% in the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company's stock valued at $256,000 after purchasing an additional 111 shares during the last quarter. TFB Advisors LLC grew its position in shares of Gilead Sciences by 1.2% during the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company's stock worth $788,000 after buying an additional 116 shares during the period. Sumitomo Life Insurance Co. raised its stake in shares of Gilead Sciences by 0.7% during the third quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company's stock worth $1,494,000 after buying an additional 117 shares during the last quarter. Finally, FDx Advisors Inc. boosted its stake in Gilead Sciences by 2.2% in the third quarter. FDx Advisors Inc. now owns 5,365 shares of the biopharmaceutical company's stock valued at $450,000 after acquiring an additional 117 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on GILD. Sanford C. Bernstein initiated coverage on Gilead Sciences in a report on Thursday, October 17th. They issued an "outperform" rating and a $105.00 price objective on the stock. Piper Sandler increased their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Oppenheimer upped their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. Daiwa America raised Gilead Sciences to a "hold" rating in a research note on Monday, November 18th. Finally, Cantor Fitzgerald upped their price target on shares of Gilead Sciences from $70.00 to $80.00 and gave the company a "neutral" rating in a report on Thursday, November 7th. Twelve investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and four have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus price target of $95.41.
View Our Latest Report on GILD
Gilead Sciences Company Profile
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
